These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 19100448)
1. Conversion to sirolimus in kidney-pancreas and pancreas transplantation. Matias P; Araujo MR; Romão JE; Abensur H; Noronha IL Transplant Proc; 2008 Dec; 40(10):3601-5. PubMed ID: 19100448 [TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up of 100 high-risk renal transplant recipients converted from calcineurin inhibitors to sirolimus: a single center experience. Halim MA; Al-Otaibi T; Johny KV; Hamid MH; Tawab KA; Balaha MA; Abraham M; Said T; Nair MP; Al-Waheeb S; Al-Muzairai I; Nampoory MR Transplant Proc; 2009 Jun; 41(5):1666-70. PubMed ID: 19545704 [TBL] [Abstract][Full Text] [Related]
3. Conversion from calcineurin inhibitor to either mycophenolate mofetil or sirolimus improves renal function in liver transplant recipients with chronic kidney disease: results of a prospective randomized trial. Herlenius G; Felldin M; Nordén G; Olausson M; Bäckman L; Gustafsson B; Friman S Transplant Proc; 2010 Dec; 42(10):4441-8. PubMed ID: 21168715 [TBL] [Abstract][Full Text] [Related]
5. Conversion from calcineurin inhibitors to sirolimus of recipients with chronic kidney graft disease grade III for a period 2003-2011. Ignjatović L; Hrvacević R; Jovanović D; Kovacević Z; Vavić N; Rabrenović V; Tomić A; Aleksić P; Drasković-Pavlović B; Dujić A; Karan Z; Maksić D Vojnosanit Pregl; 2013 Sep; 70(9):848-53. PubMed ID: 24266313 [TBL] [Abstract][Full Text] [Related]
6. Outcomes with conversion from calcineurin inhibitors to sirolimus after renal transplantation in the context of steroid withdrawal or steroid continuation. Egbuna OI; Davis RB; Chudinski R; Pavlakis M; Rogers C; Molakatalla P; Johnson SR; Karp S; Monaco AP; Tang H; Hanto DW; Mandelbrot DA Transplantation; 2009 Sep; 88(5):684-92. PubMed ID: 19741466 [TBL] [Abstract][Full Text] [Related]
7. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes. Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960 [TBL] [Abstract][Full Text] [Related]
8. Influence of sirolimus on proteinuria in de novo kidney transplantation with expanded criteria donors: comparison of two CNI-free protocols. Diekmann F; Gutiérrez-Dalmau A; López S; Cofán F; Esforzado N; Ricart MJ; Rossich E; Saval N; Torregrosa JV; Oppenheimer F; Campistol JM Nephrol Dial Transplant; 2007 Aug; 22(8):2316-21. PubMed ID: 17452413 [TBL] [Abstract][Full Text] [Related]
9. Conversion to sirolimus in renal transplant recipients: a single-center experience. Yelken B; Caliskan Y; Ozkan O; Gorgulu N; Yazici H; Turkmen A; Sever MS Artif Organs; 2010 Aug; 34(8):E230-7. PubMed ID: 20618227 [TBL] [Abstract][Full Text] [Related]
11. Posttransplantation conversion to sirolimus-based immunosuppression: a single center experience. Saber LT; Ikeda MY; Almeida JM Transplant Proc; 2007 Dec; 39(10):3098-100. PubMed ID: 18089330 [TBL] [Abstract][Full Text] [Related]
12. Mycophenolate and sirolimus as calcineurin inhibitor-free immunosuppression improves renal function better than calcineurin inhibitor-reduction in late cardiac transplant recipients with chronic renal failure. Groetzner J; Kaczmarek I; Schulz U; Stegemann E; Kaiser K; Wittwer T; Schirmer J; Voss M; Strauch J; Wahlers T; Sohn HY; Wagner F; Tenderich G; Stempfle HU; Mueller-Ehmsen J; Schmid C; Vogeser M; Koch KC; Reichenspurner H; Daebritz S; Meiser B; Reichart B; Transplantation; 2009 Mar; 87(5):726-33. PubMed ID: 19295318 [TBL] [Abstract][Full Text] [Related]
13. Conversion to sirolimus in a population of kidney and kidney-pancreas transplant recipients. Almeida M; Martins LS; Dias L; Figueiredo MJ; Henriques AC; Sarmento AM; Cabrita A Transplant Proc; 2005; 37(6):2777-80. PubMed ID: 16182808 [TBL] [Abstract][Full Text] [Related]
17. Conversion to combined therapy with sirolimus and mycophenolate mofetil improved renal function in stable renal transplant recipients. Tsai MK; Lee CY; Hu RH; Lee PH J Formos Med Assoc; 2007 May; 106(5):372-9. PubMed ID: 17561472 [TBL] [Abstract][Full Text] [Related]
18. [Early conversion from calcineurin inhibitor to sirolimusto after renal transplantation:a prospective, open-label and non-randomized control study]. Huang H; Xie W; Wu J; Xu Y; Yu X; Ren P; Chen J Zhonghua Yi Xue Za Zhi; 2014 Nov; 94(42):3293-7. PubMed ID: 25622626 [TBL] [Abstract][Full Text] [Related]
19. Effect of early conversion from CNI to sirolimus on outcomes in kidney transplant recipients with allograft dysfunction. Paoletti E; Ratto E; Bellino D; Marsano L; Cassottana P; Cannella G J Nephrol; 2012; 25(5):709-18. PubMed ID: 22038336 [TBL] [Abstract][Full Text] [Related]
20. Mycophenolate mofetil versus enteric-coated mycophenolate sodium after simultaneous pancreas-kidney transplantation. Rangel EB; Melaragno CS; Sá JR; Gonzalez AM; Linhares MM; Salzedas A; Medina-Pestana JO Transplant Proc; 2009 Dec; 41(10):4265-9. PubMed ID: 20005381 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]